Sepsis and septic shock: Inching forwards

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 9, Issue 3, 2009, Pages 256-257

  Cohen, Jonathan ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TOLL LIKE RECEPTOR; ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

ARTICLE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; MORTALITY; PATIENT CARE; SEPSIS; SEPTIC SHOCK; CLINICAL COMPETENCE; GLUCOSE BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; CLINICAL COMPETENCE; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SHOCK, SEPTIC;

EID: 69049105654     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.9-3-256     Document Type: Article

References (18)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-4.
2. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
3. Levy MM, Fink MP, Marshall JC, Abraham E et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
4. Carlet J, Cohen J, Calandra T, Opal S, Masur H. Sepsis: Time to reconsider the concept. Crit Care Med 2008;36:964-6.
5. Modernising Medical Careers. Available from: www.mmc.nhs.uk/pages/ foundation/Curriculum
6. Dellinger RP, Carlet J, Masur H et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004;30:536-55.
7. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
8. Sprung C, Caralis PV, Marcial EH et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984;311:1137-43.
9. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
10. Sprung CL, Annane D, Keh D et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
11. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
12. Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
13. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
14. Bernard GR, Vincent J-L, Laterre PF et al. Efficacy and safety of recombinant human activated Protein C for severe sepsis. N Engl J Med 2001;344:699-709.
15. National Institute for Health and Clinical Excellence. Drotrecogin alfa (activated) for severe sepsis. London: NICE, 2004.
16. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41.
17. Lynn M, Rossignol DP, Wheeler JL et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003;187:631-9.
18. Kawamoto T, Sha T, Ii M, Kimura H. Selective inhibition of Toll-like receptor 4 signaling by the small molecule TAK-242. Critical Care 2006;10(Suppl 1):S65.